Kleiner Perkins backs iZumi Bio's stem cell research

06/17/2008 | San Francisco Chronicle

Kleiner Perkins Caufield & Byers will invest in iZumi Bio, a biotech firm working on reprogramming adult cells to regain the properties of embryonic stem cells. IZumi announced Monday that it will collaborate with the J. David Gladstone Institutes in San Francisco to focus on research involving "induced pluripotent stem cells."

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN